Curaleaf Holdings

Medical Cannabis Legalization And Wellness Trends Will Redefine Market Opportunities

AnalystHighTarget

Not Invested

Community Contributor

Published

06 Aug 25

AnalystHighTarget's Fair Value

CA$4.51

2.9% undervalued

10 Sep

CA$4.38

9.5%

-1.6%

9.5%

-1.6%

You can edit this narrative until Aug 6 9:26 PM. Then, changes will post as Updates.

Author's Valuation

CA$4.512.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CA$4.51

2.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.86%

Pharma revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.30%

Calculation

US$23.73m

Earnings '28

133.60x

PE Ratio '28

US$3.17b

Market Cap '28

US$3.17b

Market Cap '28

811.13m

No. shares '28

US$3.91

Share Price '28

US$3.91 Share Price '28

Discounted to 2025 @ 6.30% p.a.

US$3.25

Fair Value '25

US$3.25 Fair Value '25

Converted to CAD @ 1.3864 USD/CAD Exchange Rate

CA$4.51

Fair Value '25